Come up with a name for your new list and we'll add to it:
NexImmune was acquired by
Sol Barer and
William Hawkins on February 14, 2017.
NexImmune is an early stage biopharmaceutical company developing immuno-therapeutics based on the Artificial IMmune (AIM) technology. The AIM technology provides an important advance in the developmen…